tirzepatide mash phase 3 Nearly 62% achieve resolution without worsening of fibrosis with What's new in treating MASH

Cutting essential, cheap, effective treatment for thousands of people through a lack of understanding of a common condition is beyond foolish

Berndt SI, Gustafsson S, Mgi R, Ganna A, Wheeler E, Feitosa MF, et al

Discard it

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has even more limited reproductive safety data since it is newer than semaglutide

In 2023, from January to November, Americas Poison Centers have reported recording nearly 2,941 calls related to semaglutide, marking a more than 15-fold increase compared to 2019

The repair window is longer, environmental stress is lower, and you're probably spending more time indoors where conditions are controlled